Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy

Jian Qiao, Mahua Dey, Alan L. Chang, Julius W. Kim, Jason Miska, Alex Ling, Dirk M Nettlebeck, Yu Han, Lingjiao Zhang, Maciej S. Lesniak

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor and is associated with poor survival. Virotherapy is a promising candidate for the development of effective, novel treatments for GBM. Recent studies have underscored the potential of virotherapy in enhancing antitumor immunity despite the fact that its mechanisms remain largely unknown. Here, using a syngeneic GBM mouse model, we report that intratumoral virotherapy significantly modulates the tumor microenvironment. We found that intratumoral administration of an oncolytic adenovirus, AdCMVdelta24, decreased tumor-infiltrating CD4+ Foxp3+ regulatory T cells (Tregs) and increased IFNγ-producing CD8+ T cells in treated tumors, even in late stage disease in which a highly immunosuppressive tumor microenvironment is considered to be a significant barrier to immunotherapy. Importantly, intratumoral AdCMVdelta24 treatment augmented systemically transferred tumor-antigen-specific T cell therapy. Furthermore, mechanistic studies showed (1) downregulation of Foxp3 in Tregs that were incubated with media conditioned by virus-infected tumor cells, (2) downregulation of indoleamine 2,3 dioxygenase 1 (IDO) in glioma cells upon infection by AdCMVdelta24, and (3) reprograming of Tregs from an immunosuppressive to a stimulatory state. Taken together, our findings demonstrate the potency of intratumoral oncolytic adenoviral treatment in enhancing antitumor immunity through the regulation of multiple aspects of immune suppression in the context of glioma, supporting further clinical development of oncolytic adenovirus-based immune therapies for malignant brain cancer.

Original languageEnglish (US)
JournalOncoImmunology
Volume4
Issue number8
DOIs
StatePublished - Jan 1 2015

Fingerprint

Neoplasm Antigens
Cell- and Tissue-Based Therapy
Glioma
Glioblastoma
T-Lymphocytes
Tumor Microenvironment
Immunosuppressive Agents
Adenoviridae
Brain Neoplasms
Immunity
Down-Regulation
Indoleamine-Pyrrole 2,3,-Dioxygenase
Oncogenic Viruses
Regulatory T-Lymphocytes
Therapeutics
Conditioned Culture Medium
Immunotherapy
Neoplasms
Infection

Keywords

  • glioblastoma
  • immunosuppression
  • immunotherapy
  • oncolytic adenovirus
  • regulatory T cells
  • Tregs
  • tumor microenvironment
  • virotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. / Qiao, Jian; Dey, Mahua; Chang, Alan L.; Kim, Julius W.; Miska, Jason; Ling, Alex; M Nettlebeck, Dirk; Han, Yu; Zhang, Lingjiao; Lesniak, Maciej S.

In: OncoImmunology, Vol. 4, No. 8, 01.01.2015.

Research output: Contribution to journalArticle

Qiao, Jian ; Dey, Mahua ; Chang, Alan L. ; Kim, Julius W. ; Miska, Jason ; Ling, Alex ; M Nettlebeck, Dirk ; Han, Yu ; Zhang, Lingjiao ; Lesniak, Maciej S. / Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. In: OncoImmunology. 2015 ; Vol. 4, No. 8.
@article{51479cac7ba14ba99fcef7f1f824a785,
title = "Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy",
abstract = "Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor and is associated with poor survival. Virotherapy is a promising candidate for the development of effective, novel treatments for GBM. Recent studies have underscored the potential of virotherapy in enhancing antitumor immunity despite the fact that its mechanisms remain largely unknown. Here, using a syngeneic GBM mouse model, we report that intratumoral virotherapy significantly modulates the tumor microenvironment. We found that intratumoral administration of an oncolytic adenovirus, AdCMVdelta24, decreased tumor-infiltrating CD4+ Foxp3+ regulatory T cells (Tregs) and increased IFNγ-producing CD8+ T cells in treated tumors, even in late stage disease in which a highly immunosuppressive tumor microenvironment is considered to be a significant barrier to immunotherapy. Importantly, intratumoral AdCMVdelta24 treatment augmented systemically transferred tumor-antigen-specific T cell therapy. Furthermore, mechanistic studies showed (1) downregulation of Foxp3 in Tregs that were incubated with media conditioned by virus-infected tumor cells, (2) downregulation of indoleamine 2,3 dioxygenase 1 (IDO) in glioma cells upon infection by AdCMVdelta24, and (3) reprograming of Tregs from an immunosuppressive to a stimulatory state. Taken together, our findings demonstrate the potency of intratumoral oncolytic adenoviral treatment in enhancing antitumor immunity through the regulation of multiple aspects of immune suppression in the context of glioma, supporting further clinical development of oncolytic adenovirus-based immune therapies for malignant brain cancer.",
keywords = "glioblastoma, immunosuppression, immunotherapy, oncolytic adenovirus, regulatory T cells, Tregs, tumor microenvironment, virotherapy",
author = "Jian Qiao and Mahua Dey and Chang, {Alan L.} and Kim, {Julius W.} and Jason Miska and Alex Ling and {M Nettlebeck}, Dirk and Yu Han and Lingjiao Zhang and Lesniak, {Maciej S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/2162402X.2015.1022302",
language = "English (US)",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy

AU - Qiao, Jian

AU - Dey, Mahua

AU - Chang, Alan L.

AU - Kim, Julius W.

AU - Miska, Jason

AU - Ling, Alex

AU - M Nettlebeck, Dirk

AU - Han, Yu

AU - Zhang, Lingjiao

AU - Lesniak, Maciej S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor and is associated with poor survival. Virotherapy is a promising candidate for the development of effective, novel treatments for GBM. Recent studies have underscored the potential of virotherapy in enhancing antitumor immunity despite the fact that its mechanisms remain largely unknown. Here, using a syngeneic GBM mouse model, we report that intratumoral virotherapy significantly modulates the tumor microenvironment. We found that intratumoral administration of an oncolytic adenovirus, AdCMVdelta24, decreased tumor-infiltrating CD4+ Foxp3+ regulatory T cells (Tregs) and increased IFNγ-producing CD8+ T cells in treated tumors, even in late stage disease in which a highly immunosuppressive tumor microenvironment is considered to be a significant barrier to immunotherapy. Importantly, intratumoral AdCMVdelta24 treatment augmented systemically transferred tumor-antigen-specific T cell therapy. Furthermore, mechanistic studies showed (1) downregulation of Foxp3 in Tregs that were incubated with media conditioned by virus-infected tumor cells, (2) downregulation of indoleamine 2,3 dioxygenase 1 (IDO) in glioma cells upon infection by AdCMVdelta24, and (3) reprograming of Tregs from an immunosuppressive to a stimulatory state. Taken together, our findings demonstrate the potency of intratumoral oncolytic adenoviral treatment in enhancing antitumor immunity through the regulation of multiple aspects of immune suppression in the context of glioma, supporting further clinical development of oncolytic adenovirus-based immune therapies for malignant brain cancer.

AB - Glioblastoma multiforme (GBM) is the most aggressive form of primary brain tumor and is associated with poor survival. Virotherapy is a promising candidate for the development of effective, novel treatments for GBM. Recent studies have underscored the potential of virotherapy in enhancing antitumor immunity despite the fact that its mechanisms remain largely unknown. Here, using a syngeneic GBM mouse model, we report that intratumoral virotherapy significantly modulates the tumor microenvironment. We found that intratumoral administration of an oncolytic adenovirus, AdCMVdelta24, decreased tumor-infiltrating CD4+ Foxp3+ regulatory T cells (Tregs) and increased IFNγ-producing CD8+ T cells in treated tumors, even in late stage disease in which a highly immunosuppressive tumor microenvironment is considered to be a significant barrier to immunotherapy. Importantly, intratumoral AdCMVdelta24 treatment augmented systemically transferred tumor-antigen-specific T cell therapy. Furthermore, mechanistic studies showed (1) downregulation of Foxp3 in Tregs that were incubated with media conditioned by virus-infected tumor cells, (2) downregulation of indoleamine 2,3 dioxygenase 1 (IDO) in glioma cells upon infection by AdCMVdelta24, and (3) reprograming of Tregs from an immunosuppressive to a stimulatory state. Taken together, our findings demonstrate the potency of intratumoral oncolytic adenoviral treatment in enhancing antitumor immunity through the regulation of multiple aspects of immune suppression in the context of glioma, supporting further clinical development of oncolytic adenovirus-based immune therapies for malignant brain cancer.

KW - glioblastoma

KW - immunosuppression

KW - immunotherapy

KW - oncolytic adenovirus

KW - regulatory T cells

KW - Tregs

KW - tumor microenvironment

KW - virotherapy

UR - http://www.scopus.com/inward/record.url?scp=84940563718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940563718&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1022302

DO - 10.1080/2162402X.2015.1022302

M3 - Article

C2 - 26405578

AN - SCOPUS:84940563718

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

ER -